Corcept Therapeutics price target raised to $130 from $78 at Canaccord
Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $130 from $78 and keeps a Buy rating on the shares. The firm is ...
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Consensus PT from Analysts
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has earned an average recommendation of “Buy” from the five ratings firms that are covering the company, Marketbeat reports. Five ...